Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Regeneron Pharmaceuticals

Main (gene editing) focus: Gene editing for genetic diseases

Company stage: Commercial

Diseases: Transthyretin (ATTR) Amyloidosis, hemophilia A and B, multiple undisclosed

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ: REGN)

Location: Tarrytown, NY, USA



Partners: Intellia Therapeutics

Regeneron is a public, large pharma company that has been in operation since 1988. The company is focusing on a broad range of diseases, but has recently struck up a partnership deal with Intellia Therapeutics. Together, the two companies are developing both in vivo and ex vivo based therapies. The most advanced programme, NTLA-2001 is being developed as a one-time, in vivo treatment for Transthyretin (ATTR) Amyloidosis.


HashtagRegeneron Pharmaceuticals, Inc.

Company: Regeneron Pharmaceuticals
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine